Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer

Eur Urol. 2018 Jun;73(6):868-869. doi: 10.1016/j.eururo.2017.10.037. Epub 2017 Nov 21.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Humans
  • Male
  • Prostate-Specific Antigen*
  • Prostatic Neoplasms*
  • Risk
  • Watchful Waiting

Substances

  • Prostate-Specific Antigen